{"id":1866,"date":"2024-09-10T08:53:28","date_gmt":"2024-09-10T08:53:28","guid":{"rendered":"https:\/\/www.fertitheralabs.gr\/?page_id=1866"},"modified":"2025-09-19T11:21:31","modified_gmt":"2025-09-19T11:21:31","slug":"urinary-uncontinence-ui","status":"publish","type":"page","link":"https:\/\/www.fertitheralabs.gr\/en\/urinary-uncontinence-ui\/","title":{"rendered":"Urinary \u0399ncontinence (UI)"},"content":{"rendered":"
\n
\n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\tUrinary \u0399ncontinence (UI)\t\t\t\t\t\t<\/h1>\n\t\t\t\t\t\t<\/div>\n<\/div><\/div>
\t
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\tOverview of Urinary \u0399ncontinence (UI)\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\tIt is the inability to control the blader and subsequent unwanted urine loss. It is a very common problem. The severity of incontinence, ranges from occasionally leaking urine when someone coughs or sneezes (Stress incontinence) to experiencing a strong urge to urinate that leads to not being able to reach WC before it\u2019s too late (Urge incontinence). There is also a mixed type of incontinence which shares symptoms with both above types.\nIt is more common as people get older, but incontinence is not a direct consequence of aging. In general, incontinence is not considered to be a disease, but a symptom and can be managed with the help of your HCP.\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\tEpidemiology\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

In women, moderate and severe bother have a prevalence ranging from about 3% to 17%. Severe incontinence has a low prevalence in young women, but rapidly increases at ages 70 through 80. In men, the prevalence of incontinence is much lower than in women, about 3% to 11% overall, with urge incontinence accounting for 40% to 80% of all male patients. Stress incontinence accounts for less than 10% of cases and is attributable to prostate surgery, trauma, or neurological injury. Incontinence in men also increases with age, but severe incontinence in 70- to 80-year-old men is about half of that in women.<\/p>\n\nbibliography: Rev Urol. 2001; 3(Suppl 1): S2\u2013S6. PMCID: PMC1476070 PMID: 16985992\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>

\n
\n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div>
\n\t
\n\t\t\t\n\t\t\t
\n\t\t\t\t\t\t\t\tFlower Pollen Extract Graminex\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\n\t\t\t
\n\t\t\t\t\t\t\t\tSaw Palmetto\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\n\t\t\t
\n\t\t\t\t\t\t\t\tZn\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div>\n\n\t
\n\t\t\t
\n\t\t\t\n\t\t\t\t
\n
\n

Flower Pollen Extract Graminex<\/h1>\n

\"Pelvax<\/p>\n<\/div>\n

\n

\u201c\u2026All the groups demonstrated improvement in ICIQ-SF scores at week 24 (p < 0.001). The RCT Fem\u2122 (Pollen extract) UI group had the greatest improvement in ICIQ-SF scores (\u22124.07 \u00b1 3.4), followed by the PollenBerry\u00ae (pollen extract) group (\u22123.34 \u00b1 2.87)\u2026\"<\/p>\n

Conclusions
\nPollen extract (RCT Fem\u2122) supplementation resulted in significant and clinically meaningful reductions in UI severity, with corresponding improvements in daily urinary leakage volume and frequency of nocturia. Pollen extract (PollenBerry\u00ae) significantly improved stress-induced urinary leakage volume, suggesting that it may be efficacious in women who are prone to stress UI. The study products were safe and well tolerated in this population.\u201d
\nBibliography: Current Urology 18(3):p 203-211, September 2024. | DOI: 10.1097\/CU9.0000000000000248<\/p>\n

\u201c\u2026A review of placebo-controlled trials, active-controlled and open-label studies indicate that Cernitin (Graminex Pollen extract content) is a safe and effective therapy for the management of mild to moderate LUTS. By reducing bothersome symptoms, Cernitin improves quality of life. The placebocontrolled, double-blind studies with Cernitin alone and combined with other natural products especially provide evidence that Cernitin is effective in reducing nocturia, daytime frequency, and sensation of residual urine\u2026. Concerning the use of Cernitin alone, we report on 15 open label studies and 4 double-blind, placebocontrolled studies that showed consistent reduction in subjective symptoms and overall effectiveness ratings of 75% and greater\u2026\u201d
\nbibliography: Research Communications in Pharmacology and Toxicology 8(1) 8(1), January 2003. A Critical Review of Cernitin\u2122 for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men, National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, University of Mississippi, University, Ms. 38677 January 12, 2003. A Critical Review of Graminex Flower pollen extract for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men<\/p>\n

\u201c\u2026Preoperatively there was no significative difference in IPSS, BS and VAS. IPSS Group A was postoperatively 7.13 (SD 1.64) and Group B was 7.33 (SD 1.58) (p=0.67); BS Group A was postoperatively 1.33 (SD 0.81), Group B was 1.73 (SD 1.09) (p=0.30), and VAS Group A was 2.73 (SD 1.9) and Group B was 4.33 (SD 1.58) (p=0.004) showing a statistically significative difference between the two groups in pelvic discomfort with a better outcome in patients treated with Graminex Pollen Extract (Cernilen-flogo\u00ae). CONCLUSIONS: Our study showed that Cernilen-flogo\u00ae treatment after PVP is effective and minimize patient\u2019s pelvic discomfort showed by lower VAS level resulting in better postoperatively patient\u2019s quality of life (QOL)\u2026\u201d
\nBibliography: European Review for Medical and Pharmacological Sciences 2020; 24: 9116-9120. Postoperative treatment with phytotheraphy Graminex G63 (CERNILEN-Flogo\u00ae) after greenlight laser XPS (180W) photovaporization of the prostate (PVP), can affect patient\u2019s quality of life?<\/p>\n<\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t

\n\t\t\t\n\t\t\t\t
\n
\n

Extract Saw Palmetto<\/h1>\n

\"Pelvax<\/p>\n<\/div>\n

\n

\u201c\u2026The daytime frequency score in the core lower urinary symptom score (CLSS) questionnaire was significantly lower in women with LUTS treated with SPE for 12 weeks than in the placebo group. A subgroup analysis revealed that SPE alleviated the symptoms of daytime frequency (CLSS Q1) and nocturia (CLSS Q2) in a subset of subjects with a CLSS Q5 score of 1 or higher. The daytime frequency of urination in overactive bladder symptom score (OABSS) Q1 was also significantly improved by the SPE treatment. In conclusion, the present study is the first to demonstrate the potential of SPE to mitigate LUTS in adult women\u2026\u201d
\nBibliography: Nutrients 2022, 14(6), 1190; https:\/\/doi.org\/10.3390\/nu14061190<\/a><\/p>\n

\u201c\u2026Thus, SPE at clinically relevant doses may exert a direct effect on the pharmacological receptors in the lower urinary tract, thereby improving urinary dysfunction in patients with BPH and an overactive bladder. SPE does not have interactions with co-administered drugs or serious adverse events in blood biochemical parameters, suggestive of its relative safety, even with long-term intake. Clinical trials (placebo-controlled and active-controlled trials) of SPE conducted in men with BPH were also reviewed. This review should contribute to the understanding of the pharmacological effects of SPE in the treatment of patients with BPH and associated lower urinary tract symptoms (LUTS)\u2026\u201d
\nBibliography: Acta Pharmacologica Sinica volume 30, pages271\u2013281 (2009)<\/p>\n

\u201c\u2026Eighty-two patients participated in the 8-week trial, taking one capsule of 320\u2009mg saw palmetto extract daily. At the end of the treatment, the International Prostate Symptom Score was reduced from 14.4\u2009\u00b1\u20094.7 to 6.9\u2009\u00b1\u20095.2 (p\u2009<\u20090.0001); SDys measured with the brief Sexual Function Inventory improved from 22.4\u2009\u00b1\u20097.2 to 31.4\u2009\u00b1\u20099.2 (p\u2009<\u20090.0001), and the Urolife BPH QoL-9 sex total improved from 137.3\u2009\u00b1\u200947.9 to 195.0\u2009\u00b1\u200956.3 (p\u2009<\u20090.0001). Investigators' and patients' assessments confirmed the good efficacy, and treatment was very well tolerated and accepted by the patients. Correlation analyses confirmed the relationship between improved BPH symptoms and reduced SDys. This was the first trial with saw palmetto to show improvement in BPH symptoms and SDys as well\u2026\u201d
\nBibliography: https:\/\/doi.org\/10.1002\/ptr.4696<\/a><\/p>\n<\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t

\n\t\t\t\n\t\t\t\t
\n
\n

Zn<\/h1>\n

\"Pelvax<\/p>\n<\/div>\n

\n

\u201c\u2026To date, the only epidemiologic study to have published data on the relationship between dietary micronutrient composition and LUTS in women has been the UK Leicestershire MRC Incontinence Study, which examined 1-yr incidence of overactive bladder (OAB; as defined by urgency symptoms or urge urinary incontinence) or stress-related urinary incontinence. Results showed positive associations between zinc and stress urinary incontinence\u2026\u201d
\nBibliography: European Urology Volume 59, Issue 6, June 2011, Pages 1039-1047<\/p>\n<\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>

\t\t\t

** All data above are published as clinical trials and do not refer to EFSA claims. This means that they do not intend to be medical or therapeutical advice.<\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Urinary \u0399ncontinence (UI) It is the inability to control the blader and subsequent unwanted urine loss. It is a very common problem. The severity of incontinence, ranges from occasionally leaking urine when someone coughs or sneezes (Stress incontinence) to experiencing a strong urge to urinate that leads to not being able to reach WC before …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"slim_seo":{"description":"Urinary \u0399ncontinence (UI) is the inability to control the blader and subsequent unwanted urine loss.","title":"Urinary \u0399ncontinence (UI) - Fertithera Labs"},"footnotes":""},"class_list":{"0":"post-1866","1":"page","2":"type-page","3":"status-publish","5":"clearfix","6":"article"},"_links":{"self":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages\/1866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/comments?post=1866"}],"version-history":[{"count":24,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages\/1866\/revisions"}],"predecessor-version":[{"id":2259,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages\/1866\/revisions\/2259"}],"wp:attachment":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/media?parent=1866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}